A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy

[1]  A. Kjær,et al.  Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study , 2013, Radiation oncology.

[2]  J. Bussink,et al.  Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[3]  V Grégoire,et al.  Implementation of hypoxia PET imaging in radiation therapy planning. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  D. Ball,et al.  Imaging of hypoxia with 18F‐FAZA PET in patients with locally advanced non‐small cell lung cancer treated with definitive chemoradiotherapy , 2013, Journal of medical imaging and radiation oncology.

[5]  Steen Jakobsen,et al.  FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  John L. Humm,et al.  Image-Guided Po2 Probe Measurements Correlated with Parametric Images Derived from 18F-Fluoromisonidazole Small-Animal PET Data in Rats , 2012, The Journal of Nuclear Medicine.

[7]  Yihui Guan,et al.  18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO , 2012, Nuclear medicine communications.

[8]  Anne Bol,et al.  Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Johannes H Kaanders,et al.  Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Tadashi Kamada,et al.  Results of carbon ion radiotherapy for head and neck cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  B. S. Sørensen,et al.  Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. , 2012, Seminars in radiation oncology.

[12]  S. Jakobsen,et al.  PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Fréderic Duprez,et al.  Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Fréderic Duprez,et al.  Adaptive dose painting by numbers for head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[15]  Vincent Gregoire,et al.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. , 2011, Seminars in radiation oncology.

[16]  M. Welch,et al.  Positron Emission Tomography Imaging of Hypoxia. , 2009, PET clinics.

[17]  V. Grégoire,et al.  Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  Marko Seppänen,et al.  18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer , 2008, Journal of Nuclear Medicine.

[19]  J. C. Martínez,et al.  Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin. , 2008, International journal of radiation oncology, biology, physics.

[20]  J. Bussink,et al.  Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. , 2008, International journal of radiation oncology, biology, physics.

[21]  M. Schwaiger,et al.  Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[22]  R. Fisher,et al.  Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. , 2007, International journal of radiation oncology, biology, physics.

[23]  D. Olsen,et al.  Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. , 2007, International journal of radiation oncology, biology, physics.

[24]  Daniela Thorwarth,et al.  Hypoxia dose painting by numbers: a planning study. , 2007, International journal of radiation oncology, biology, physics.

[25]  Barbara Vanderstraeten,et al.  Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[26]  M. Picchio,et al.  Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[28]  Thomas Scholbach,et al.  pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? , 2007, BMC Cancer.

[29]  D. Hristov,et al.  Adapting radiotherapy to hypoxic tumours , 2006, Physics in medicine and biology.

[30]  Martin Westhofen,et al.  FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  D. Mankoff,et al.  Hypoxia imaging-directed radiation treatment planning , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[34]  V. Grégoire,et al.  Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  Daniela Thorwarth,et al.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.

[36]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  C. Solbach,et al.  Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[38]  Morand Piert,et al.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  M. Eble,et al.  pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose) , 2004, Strahlentherapie und Onkologie.

[40]  V. Grégoire,et al.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3 , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  V. Grégoire,et al.  In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  Tove Grönroos,et al.  Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  M. Welch,et al.  PET imaging of hypoxia. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[44]  P Vaupel,et al.  Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. , 2001, Seminars in oncology.

[45]  G. Calais,et al.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. , 1999, Journal of the National Cancer Institute.

[46]  A. Fyles,et al.  Oxygenation predicts radiation response and survival in patients with cervix cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  J. Overgaard,et al.  Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. , 1996, Seminars in radiation oncology.

[48]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[49]  P Vaupel,et al.  Pathophysiological approaches to identifying tumor hypoxia in patients. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[50]  T. Pajak,et al.  A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). , 1989, International journal of radiation oncology, biology, physics.

[51]  L. V. Coleman.  A planning study , 1950 .